Product Dossier
NINLARO
Product Dossier for NINLARO (ixazomib, Takeda Pharmaceuticals). ARTG record, PBS listing, PBAC outcomes, AusPAR — compiled by arcimedes.
- Sponsor: Takeda Pharmaceuticals
- Active ingredient: ixazomib
- Therapeutic area: Oncology
- Same area: TALZENNA
- Same area: ZARZIO
What it is
NINLARO is ixazomib citrate, supplied as capsules in strengths of 2.3 mg, 3 mg, and 4 mg.
Approved indications
— In combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Regulatory history
NINLARO received TGA approval on 2016-11-10. ARTG registrations for all three strengths were first listed on 2016-11-15.